Oncology Evolved

Engineering the Next Generation of Off-the-Shelf Cell Therapies

learn about WU-CART

PIPELINE

learn more

PRE-CLINICAL

CLINICAL

CAR-T (Allogeneic)

T-ALL/LBL

T-NHL

AML

Autoimmune

LATEST NEWS

learn more

Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007

— Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth,…

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response…

Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer

ST. LOUIS, MO and SAN DIEGO, CA, Feb. 26, 2025 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf…

OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

About Wugen

Wugen is a clinical-stage biotechnology company

Science

Cellular therapies originating from healthy donors

Contact us

Get in touch with us if you have any questions